Stock News & Analysis

The company crushed bottom-line estimates in its final quarter of 2025.

This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.

Investors are concerned about restrictive regulations against social media companies.

Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.

The outcome for investors could be more complex than it seems.

The war in Iran is driving widespread selling in the stock market.

The performance came from an unlikely source for this company.

Trader barriers are increasing import prices for most businesses, including e.l.f.

Drivers are paying higher fuel prices.

One analyst tracking the stock shaved $10 off his price target.

Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance.

Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern.

It underwent a rather surprising C-suite change.

How does a divided yield topping 5% sound?

On March 27, 2026, investors weighed Unity’s Vector AI-fueled Q1 revenue hike against a sweeping overhaul of its ads and gaming portfolio.

CrowdStrike's top-line growth remains impressive, but a demanding valuation leaves the stock vulnerable to emerging artificial intelligence risks.

Sandisk stock has soared over 1,610% since its spinoff from Western Digital in February 2025.

HSBC's lead analyst on Tesla thinks the stock could fall to $131 per share.

It failed to meet expectations for its final quarter of 2025.

Beyond Meat stock could be heading for some big changes in the not-too-distant future.